Related Experiment Video
Updated: Sep 12, 2025
04:27
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
5.7K
THERAPIES FOR NEONATAL DISEASES OF THE SURFACTANT SYSTEM
1Iowa City, IA.
Summary
Genetic mutations in surfactant proteins (SFTPB, SFTPC) and ABCA3 disrupt lung function. Gene therapies offer potential treatments for these critical respiratory diseases.
Area of Science:
- Pulmonary Medicine
- Genetics
- Cell Biology
Background:
- Pulmonary surfactant, produced by alveolar type II (AT2) cells, is essential for infant respiration.
- Surfactant comprises phospholipids and proteins (SP-B, SP-C), crucial for alveolar function.
- Mutations in SFTPB, SFTPC, and ABCA3 genes cause severe respiratory distress and interstitial lung diseases.
Purpose of the Study:
- To explore the genetic basis of surfactant dysfunction.
- To investigate the potential of genetic therapies for treating related lung diseases.
Main Methods:
- Analysis of genetic mutations in SFTPB, SFTPC, and ABCA3.
- Review of current therapeutic strategies and their limitations.
- Exploration of gene addition and gene editing as potential treatments.
Main Results:
- Loss-of-function mutations in SFTPB and ABCA3, and dominant mutations in SFTPC, lead to severe respiratory conditions.
- No specific treatments are currently available for these genetic lung diseases.
- Genetic therapies present a promising avenue for correcting the underlying molecular defects.
Conclusions:
- Genetic defects in surfactant production cause significant respiratory morbidity.
- Gene-based therapeutic strategies hold promise for treating these debilitating lung diseases.
More Related Videos
04:21A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease
Published on: August 4, 2021
6.2K
06:15Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
50.4K
Related Concept Videos
01:05Breathing
60.3K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
60.3K
01:29Acute Respiratory Failure-V
208
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
208
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
434
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
434
01:24Cystic Fibrosis: Management
224
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
224
01:17Drugs Used in Lower Respiratory Disorders: Overview
583
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
583
01:30Pneumonia V: Nursing management and Prevention
2.5K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.5K